Alaleh Nouri - 03 May 2024 Form 4 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Signature
/s/ Jonathan Stone, Attorney-in-Fact for Alaleh Nouri
Issuer symbol
PRCT
Transactions as of
03 May 2024
Net transactions value
-$1,707,449
Form type
4
Filing time
03 May 2024, 21:40:36 UTC
Previous filing
20 Mar 2024
Next filing
18 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRCT Common Stock Options Exercise $6,690 +1,467 +2.3% $4.56* 63,939 03 May 2024 Direct
transaction PRCT Common Stock Options Exercise $20,539 +3,965 +6.2% $5.18 67,904 03 May 2024 Direct
transaction PRCT Common Stock Options Exercise $181,750 +25,000 +37% $7.27 92,904 03 May 2024 Direct
transaction PRCT Common Stock Sale $23,788 -391 -0.42% $60.84 92,513 03 May 2024 Direct F1
transaction PRCT Common Stock Sale $94,126 -1,536 -1.7% $61.28 90,977 03 May 2024 Direct F2
transaction PRCT Common Stock Sale $874,979 -13,935 -15% $62.79 77,042 03 May 2024 Direct F3
transaction PRCT Common Stock Sale $915,017 -14,437 -19% $63.38 62,605 03 May 2024 Direct F4
transaction PRCT Common Stock Sale $8,517 -133 -0.21% $64.04 62,472 03 May 2024 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRCT Stock Option (Right to Buy) Options Exercise $0 -1,467 -11% $0.000000 12,230 03 May 2024 Common Stock 1,467 $4.56 Direct F6
transaction PRCT Stock Option (Right to Buy) Options Exercise $0 -3,965 -20% $0.000000 16,160 03 May 2024 Common Stock 3,965 $5.18 Direct F7
transaction PRCT Stock Option (Right to Buy) Options Exercise $0 -25,000 -43% $0.000000 32,894 03 May 2024 Common Stock 25,000 $7.27 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.67 to $60.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.00 to $61.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $63.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.02 to $64.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F6 The Stock option was granted on December 12, 2019 and vests on each monthly anniversary of the grant date over a four year period, subject continued employment or service to the Issuer through the applicable vesting date.
F7 The Stock option was granted on August 10, 2020 and vests 12.5% on the six month anniversary of August 1, 2020 and the remainder on each monthly anniversary over a three and a half year period, subject continued employment or service to the Issuer through the applicable vesting date.
F8 The Stock option was granted on June 22, 2021 and vests 25% on the six month anniversary of June 22, 2021 and the remainder vests on each monthly anniversary over a four year period, subject continued employment or service to the Issuer through the applicable vesting date.